Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The following are some CD99 CAR-related products we provide for customers to choose from. Meanwhile, you can search for more suitable products through the following search box.
CD99 is a 32-kDa cell surface glycoprotein that expressed in almost all leukocyte lineage cells. CD99 participates in many important biological processes, such as cell adhesion, leukocyte migration, infiltration, and transmembrane protein transport processes. Meanwhile, it influences a variety of signaling pathways associated with cancer, inflammation, and immune response. Given the features of CD99, it is a promising therapeutic target for many diseases.
Associated Diseases
For CAR structure design, we provide a variety of robust CAR construction, including classical CAR structures, special armed CAR designs, etc. At the same time, we are committed to customizing more suitable products for customers to meet the needs of the project.
Fig.1 Schematic diagram of CD99 CAR construction.1
Anti-CD99 CAR-T Expansion Test
Cell proliferation test is a relatively routine but critical test in the CART development, we provide sensitive detection experiments through a variety of detection methods, such as the MTT test, Ki 67 detection, and cell dynamic analysis.
Fig.2 Proliferation test of anti-CD99 CAR T cells for 14 days.1
Anti-CD99 CAR Expression Test
CAR expression detection is designed to analyze the CAR transfection and expression of CART cells, providing relevant data references for further experimental design. Creative Biolabs has developed a number of sensitive CAR detection reagents and related assays to verify CAR expression.
Fig.3 CAR expression test of CD99-CART cells measured by flow cytometry.1
Anti-CD99 CAR-T Cytokine Release Test
Cytokine detection is used to characterize CART-related functions and confirm the target specificity and effectiveness of the CART cells. We provide a wide range of cytokine detection tests, such as ELISA, multiple cytokine profile arrays, and intracellular cytokine tests. Meanwhile, kinds of cytokines can be detected, including but not limited to IL-2, IFN-γ, IL-6, and IL-10.
Anti-CD99 CAR-T In Vitro Cytotoxicity Assay
In vitro tumor killing experiments can effectively illustrate the clearance ability of CART cells against target cells, providing relevant references for further in vivo experiments. Creative Biolabs has launched many sensitive cytotoxicity assays for global customers to choose from, including luciferase-based cytotoxicity tests, chromium (51 chromium) release assays, flow cytometry assays, and calcein release assays.
Fig.4 Cytotoxic assessment of the CD99 CAR-T cells against target cells from T-ALL patients' blasts at indicated E:T ratios.1
Anti-CD99 CAR-T Cell Therapy Animal Models
According to different targets and project requirements, it is necessary to select appropriate animal models and corresponding experimental design schemes. With our years of experience in CART fields, we offer a wide range of relevant in vivo animal models to assist in CART development, such as CDX models, and PDX models.
Fig.5 Schematic of in vivo study design of anti-CD99 CAR-T in T-ALL CDX and PDX models.1
Efficacy Test of Anti-CD99 CAR-T
Creative Biolabs provides comprehensive in vivo pharmacodynamic evaluation services to provide the scientific basis for your preclinical studies.
Fig.6 Efficacy assessment of CD99 CAR-T in Jurkat or MOLT-4 CDX models monitored by bioluminescent imaging.1
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-0622-ZP3313 | Anti-CD99 h(VHH1-VHH2-CD28-CD3ζ) Biepitopic CAR, pCDCAR1 | Human | VHH1-VHH2-CD28-CD3ζ | Lentiviral vector | T Cell | ||||
| XS-0622-ZP3485 | Anti-CD99 h(VHH1-VHH2-4-1BB-CD3ζ) Biepitopic CAR, pCDCAR1 | VHH1-VHH2-4-1BB-CD3ζ | Lentiviral vector | T Cell | |||||
| XS-0822-YF252 | Anti-Human CD99 (XW-252) h(41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-252 | Mouse | scFv-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF1172 | Anti-Human CD99 (XW-252) h(CD28-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-252 | Mouse | scFv-CD28-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-0822-YF2092 | Anti-Human CD99 (XW-252) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-252 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
| XS-1122-LX218 | Anti-CD99 (X11X218) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X218 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX219 | Anti-CD99 (X11X219) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X219 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX220 | Anti-CD99 (X11X220) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X220 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX221 | Anti-CD99 (X11X221) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X221 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX222 | Anti-CD99 (X11X222) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | X11X222 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX612 | Anti-CD99 (X11X214) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X214 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX613 | Anti-CD99 (X11X215) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X215 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX614 | Anti-CD99 (X11X216) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X216 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX615 | Anti-CD99 (X11X217) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X217 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX616 | Anti-CD99 (X11X218) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X218 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX617 | Anti-CD99 (X11X219) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X219 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX618 | Anti-CD99 (X11X220) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X220 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX619 | Anti-CD99 (X11X221) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X221 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX620 | Anti-CD99 (X11X222) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X222 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX1010 | Anti-CD99 (X11X214) h(ICOS-4-1BB-CD3ζ) CAR, pCDCAR1 | Human | X11X214 | Humanized | scFv-ICOS-4-1BB-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
